British pharmaceutical firm AstraZeneca PLC announced on Thursday it will commit usd 15 billion (about ₹1.2 lakh crore) to expand research, development and manufacturing operations in China through 2030, underscoring the country’s growing importance in global drug innovation and production.
The investment, detailed in a company press release, aims to bolster AstraZeneca’s capabilities across the entire drug value chain from discovery and clinical development to large-scale manufacturing, particularly in cell therapies and radioconjugates, two areas of rapid scientific advance.